Lisa Ross

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms
    Lisa Ross
    International Clinical Virology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    AIDS Res Hum Retroviruses 21:933-9. 2005
  2. ncbi request reprint Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens
    L Ross
    Department of Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 17:1107-15. 2001
  3. ncbi request reprint Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort
    Lisa Ross
    Department of International Clinical Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 21:696-701. 2005
  4. ncbi request reprint Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens
    L Ross
    Department of Clinical Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    J Hum Virol 4:217-22. 2001
  5. ncbi request reprint Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy
    L Ross
    Department of Virology, GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    AIDS Res Hum Retroviruses 17:1379-85. 2001
  6. pmc Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
    L L Ross
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 65:307-15. 2010
  7. ncbi request reprint Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects
    Denise Paulsen
    Department of International Clinical Virology, GlaxoSmithKline Inc, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 52:319-23. 2003
  8. ncbi request reprint Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
    Denise Paulsen
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 18:1011-9. 2002
  9. ncbi request reprint Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
    Lisa Ross
    Department of International Clinical Virology at GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS 18:1691-6. 2004
  10. ncbi request reprint Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    HIV Clin Trials 8:1-8. 2007

Detail Information

Publications15

  1. ncbi request reprint A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms
    Lisa Ross
    International Clinical Virology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    AIDS Res Hum Retroviruses 21:933-9. 2005
    ..In conclusion, results comparing these two phenotypic tests were mostly similar, but comparisons of the predictive resistance algorithms for specific drugs, as well as to specific phenotypic assays, were more inconsistent...
  2. ncbi request reprint Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens
    L Ross
    Department of Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 17:1107-15. 2001
    ..Subjects can experience viremia on d4T-containing regimens with virus exhibiting only small increases in IC(50), suggesting that relatively small changes in viral susceptibility to d4T may influence drug efficacy...
  3. ncbi request reprint Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort
    Lisa Ross
    Department of International Clinical Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 21:696-701. 2005
    ..For those where discordance among algorithms existed, further improvement will likely occur as drug resistance pathways for the more recently approved PIs are elucidated...
  4. ncbi request reprint Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens
    L Ross
    Department of Clinical Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    J Hum Virol 4:217-22. 2001
    ....
  5. ncbi request reprint Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy
    L Ross
    Department of Virology, GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    AIDS Res Hum Retroviruses 17:1379-85. 2001
    ..For several drugs, specific combinations of drug resistance mutations are associated with decreased phenotypic susceptibility and might provide useful clinical guidelines in selecting therapeutic options...
  6. pmc Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
    L L Ross
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 65:307-15. 2010
    ....
  7. ncbi request reprint Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects
    Denise Paulsen
    Department of International Clinical Virology, GlaxoSmithKline Inc, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 52:319-23. 2003
  8. ncbi request reprint Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
    Denise Paulsen
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 18:1011-9. 2002
    ..009), NFV (p = 0.003), and IDV (p = 0.021) but not with prior SQV (p = 0.103). These results suggest that APV and LPV have different cross-resistance mutation patterns that may help determine choice of PI therapy after therapy failure...
  9. ncbi request reprint Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
    Lisa Ross
    Department of International Clinical Virology at GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS 18:1691-6. 2004
    ....
  10. ncbi request reprint Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    HIV Clin Trials 8:1-8. 2007
    ..As treatment strategies and utilization of antiretroviral drugs evolve, patterns of transmitted mutations may shift...
  11. doi request reprint Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 25:665-72. 2009
    ..These data suggest that TAMs selection is a preferred resistance route of this combination, with zidovudine modulating the resistance pathway against selection for K65R...
  12. ncbi request reprint Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    HIV Clin Trials 7:334-8. 2006
    ..In recent ritonavir-boosted protease inhibitor (PI) studies, high efficacy rates have been observed, with few PI mutations detected...
  13. ncbi request reprint Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1
    E Randall Lanier
    GlaxoSmithKline, Research Triangle Park, NC 27705, USA
    J Acquir Immune Defic Syndr 39:519-22. 2005
    ..Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination...
  14. ncbi request reprint Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 192:1921-30. 2005
    ..Antiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy. We compared 2 regimens dosed as 2 pills once daily...
  15. ncbi request reprint Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study
    Richard Elion
    George Washington University, Washington, DC, USA
    HIV Clin Trials 7:324-33. 2006
    ....